Abbisko Therapeutics Announces Positive Preliminary Phase 2 Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia
SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- 21 September 2026 (Beijing time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced positive preliminary efficacy results from the Phase II clinical study of lavengratinib (ABSK061), a selective...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Huawei Digital Power presenta a IDEE 2026 soluzioni multi-scenario con tecnologie Grid Forming e Intelligenza Artificiale
- Solidion Technology Board Appoints Jaymes Winters as Chairman and CEO; Mark Schwartz as Lead Independent Director
- Golden Week 2026 Fuels Extended Breaks and New Travel Routes: Trip.com Group Reveals Rising Destinations and Regional Trends
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →